$VERAVera Therapeutics, Inc.

📅 Upcoming

🕒 Recent(90d)

News

• Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drug
  Though it's no longer unusual for a startup to emerge with an investigational drug from China, an immunology biotech is adding that asset to two disease-controlling drugs it already discovered in-h…
  endpoints · 3h ago
• Boulevard starts up with $65M to pursue targeted autoimmune drugs
  Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.
  biopharma_dive · 3h ago
• Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
  Boulevard Bio has strolled out of stealth with $65 million in funding from Deerfield Management and three autoimmune disease candidates.
  fiercebiotech · 1d ago
• Silence causes uproar in rare blood cancer space as data sets high bar for competitors
  The mid-stage win of Silence Therapeutics’ siRNA drug in polycythemia vera validates the therapeutic approach of similar assets in development—but also sets a high standard for therapies from Taked…
  biospace · 1d ago
• Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
  Silence Therapeutics is set to advance its siRNA drug for the rare blood disorder polycythemia vera (PV) into Phase 3 following a successful mid-stage trial. Silence said Monday that its drug ...
  endpoints · 2d ago
• STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer
  A rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.
  stat · 2d ago
• Silence brings the noise to Takeda with phase 2 blood cancer win
  A phase 2 trial of Silence Therapeutics’ divesiran has hit its primary endpoint, emboldening the biotech to gear up for late-phase development of a potential challenger to Takeda and Protagonist Th…
  fiercebiotech · 2d ago
• Why Big Pharma is chasing the industry’s most-powerful supercomputer
  Bristol Myers Squibb is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.
  biopharma_dive · 5d ago
• Takeda’s narcolepsy nod opens orexin doors
  Orzeyful is the first orexin agonist cleared by the FDA, and is the first narcolepsy therapy that addresses the full host of disease symptoms. It is "likely to reshape the treatment paradigm” for t…
  biospace · 6d ago
• Vertex unfazed by competitive IgAN space as FDA verdict looms
  Positive two-year follow-up data for Otsuka Pharmaceuticals’ IgA nephropathy drug Voyxact could support the FDA’s ongoing review of Vertex Pharmaceuticals’ povetacicept, CEO Reshma Kewalramani said…
  biospace · 8d ago